[Evaluation of efficacy, safety and tolerance of glimepiride (Amaryl) in patients with type 2 diabetes].
Glimepiride is a new long-acting the third generation sulfonylurea given once daily. The aim of this study was to evaluate the efficacy, safety and tolerability of glimepiride given as monotherapy in type 2 diabetic patients. A total of 142 patients (65 women and 77 men; mean +/- SD: age 57 +/- 8.5 years, duration of diabetes 64.4 +/- 57.7 months, BMI 28.7 +/- 3.6 kg/m2) were treated during 12 weeks with glimepiride (Amaryl). Glimepiride was forced titrated 0.5-7.0 mg once daily based on efficacy. Statistical analysis our results showed significant (p < 0.001) decrease of average fasting blood glucose, twenty-four hour plasma glucose values and HbA1c significantly lower. Systolic and diastolic blood pressure was also significantly (p < 0.001; p < 0.03) lower. There was a trend to lower serum cholesterol and triglyceride levels. The other laboratory values did not change during this study. No differences were registered in body weight. Safety was assessed by evaluating vital signs, laboratory values and the occurrence of adverse events. The frequency of hypoglycaemic events was very rare (0.7%). The percentage of patients with adverse drug reactions was 6.3%. The tolerance of glimepiride was good. This study demonstrates that glimepiride is effective, safe and well tolerated in improving glycaemic control in patients with type 2 diabetes.